Related Experiment Videos
Clinical Experience with Quintuple Non-Insulin Drug Therapy in Suboptimally Controlled Type 2 Diabetes
Georgios S Papaetis1,2, Costas A Christophi3, Andriana M Till3
1K.M.P THERAPIS Paphos Medical Center, Internal Medicine and Diabetes Clinic, 14 Vasileos Georgiou B Street, Office 201, 8010, Paphos, Cyprus.
Current Drug Safety
|July 29, 2026
Summary
For Type 2 Diabetes (T2D) patients refusing insulin, five non-insulin drug combinations are a viable option. This approach showed effectiveness with no significant side effects in a recent study.
Area of Science:
- Endocrinology
- Pharmacology
- Diabetes Management
Background:
- Limited evidence exists for Type 2 Diabetes (T2D) patients refusing insulin and using five non-insulin antidiabetic drugs.
- Investigating alternative treatment strategies is crucial for this patient group.
Purpose of the Study:
- To determine the prevalence of quintuple non-insulin drug regimens in T2D patients who refuse insulin therapy.
- To assess the effectiveness and safety of these regimens.
Main Methods:
- A retrospective observational study was conducted over 12 months.
- 1463 T2D patients were assessed, with 40 meeting eligibility criteria for refusing insulin.
- Data on therapeutic period, A1C levels, and drug combinations were analyzed.
Main Results:
- The prevalence of quintuple non-insulin regimens was 2.7% (40 patients).
- The majority (70%) received pioglitazone as the fifth drug.
- A significant A1C decrease of 0.82% was observed without notable side effects (p < 0.001).
- Fear of insulin was the primary reason for refusal.
Conclusions:
- Quintuple non-insulin drug combinations are a potential therapeutic option for T2D patients refusing insulin.
- These regimens demonstrated safety and effectiveness in the studied population.
- Individualized assessment is recommended for these difficult-to-treat patients.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...